← Tarsus Pharmaceuticals, Inc.
| Annual Trend | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| Revenues: | ($40k) | $0 | $57.0m | $25.8m | $17.4m | $183.0m | $451.4m | $606.3m | |
| Cost of sales | — | — | — | $955k |
$1.6m
+66.81%
|
$12.8m
+705.15%
|
$30.7m
+139.23%
|
$40.7m
+32.79%
|
|
| Research and development | $3.2m | $18.8m | $41.7m | $42.6m | $50.3m | $53.4m | $64.3m | $87.7m | |
| Selling, general and administrative | — | — | — | $44.9m | $108.7m | $237.3m | $427.3m | $526.4m | |
| Total operating expenses | $4.3m | $27.0m | $69.2m | $88.5m | $160.6m | $303.5m | $522.3m | $614.1m | |
| Interest expense | — | — | $0 | ($2.2m) | ($3.3m) | ($7.8m) | ($8.9m) | $8.1m | |
| Interest income | — | $188k | $36k | $3.5m | $10.3m | $15.0m | $15.7m | $15.5m | |
| Unrealized gain (loss) on marketable securities and cash equivalents | — | — | $0 | ($74k) | $72k | $181k | $202k | — | |
| Loss from operations before other income (expense) | ($4.3m) | ($27.0m) | ($12.2m) | ($62.7m) | ($143.2m) | ($120.6m) | ($71.0m) | — | |
| Other income (expense), net | — | $0 | ($73k) | $86k | ($102k) | $586k | ($202k) | $2.5m | |
| Total other income, net | ($371k) | $188k | ($1.6m) | $617k | $7.3m | $5.0m | $6.6m | — | |
| Loss before income taxes | — | ($26.8m) | ($13.8m) | ($62.1m) | ($135.9m) | ($115.6m) | ($64.4m) | — | |
| Provision for income taxes | ($1k) | ($1k) | ($55k) | $4k | $0 | $0 | ($2.1m) | — | |
| Net loss | ($4.7m) | ($26.8m) | ($13.8m) | ($62.1m) | ($135.9m) | ($115.6m) | ($66.4m) | — | |
| Net loss per share, basic (usd per share) | ($2) | ($4) | ($1) | ($3) | ($5) | ($3) | ($2) | — | |
| Net loss per share, diluted (usd per share) | ($2) | ($4) | ($1) | ($3) | ($5) | ($3) | ($2) | — | |
| Weighted-average shares outstanding, basic (in shares) | — | 6.2m | 20.6m | 24.6m | 29.4m | 37.6m | 41.8m | — | |
| Weighted-average shares outstanding, diluted (in shares) | — | 6.2m | 20.6m | 24.6m | 29.4m | 37.6m | 41.8m | — | |
| Loss on debt extinguishment | ($255k) | $0 | — | $0 | $0 | ($1.9m) | $0 | — | |
| Comprehensive loss | ($4.7m) | ($26.8m) | ($13.8m) | ($62.2m) | ($135.8m) | ($115.4m) | ($66.2m) | — |